Back to Browse Journals » Clinical Interventions in Aging » Volume 7

Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome

Authors Ritchie EK

Published Date June 2012 Volume 2012:7 Pages 165—173

DOI http://dx.doi.org/10.2147/CIA.S24659

Received 29 February 2012, Accepted 16 April 2012, Published 19 June 2012

Ellen K Ritchie

Leukemia Program, Weill Medical College of Cornell University and The New York Presbyterian Hospital, New York, NY, USA

Abstract: The goals of treating older patients with myelodysplastic syndrome (MDS) are different than for younger patients. Few elderly patients are able to pursue an allogeneic stem cell transplant for potential cure of the disease. The focus for the treatment of older patients with MDS is therefore not curative, but rather alleviation of symptoms, improvement in quality of life, maintenance or improvement of functional status, and continued independent living. Prolongation of survival is only important if functional status and quality of life can be maintained, and there is greater risk of losing these outcomes in elderly patients. Azacitidine is an important drug for the treatment of older patients with MDS. Data from the AZA-001 trial has shown a survival benefit for patients with high-risk disease treated with azacitidine. Importantly, treatment has also been shown to improve quality of life for MDS patients. Subset analysis of the data has shown that the drug can be used safely in even the oldest patients with MDS and is superior to treatment with other established regimens, such as low-dose cytarabine. Given the delay between the initiation of treatment and the clinical response, patients may need aggressive supportive care with antiemetics, prophylactic antibiotics, and transfusions to maintain them through therapy. Azacitidine provides a better quality of response when it is used beyond the first response, so ongoing treatment is generally recommended in responding patients. A new oral preparation of the drug is in development that will make the treatment more feasible and comfortable for elderly patients.

Keywords: geriatrics, myelodysplastic syndrome, acute myeloid leukemia, azacitidine, supportive care

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Polyethylenimine600-β-cyclodextrin: a promising nanopolymer for nonviral gene delivery of primary mesenchymal stem cells

Tong H, Wang C, Huang Y, Shi Q, Fernandes JC, Dai K, Tang G, Zhang X

International Journal of Nanomedicine 2013, 8:1935-1946

Published Date: 24 May 2013

Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges

Rahmathulla G, Hovey EJ, Hashemi-Sadraei N, Ahluwalia MS

OncoTargets and Therapy 2013, 6:371-389

Published Date: 15 April 2013

Predictors and prevention of diabetic cardiomyopathy

Chavali V, Tyagi SC, Mishra PK

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2013, 6:151-160

Published Date: 11 April 2013

Gene mutations in cardiac arrhythmias: a review of recent evidence in ion channelopathies

Hsiao PY, Tien HC, Lo CP, Juang JM, Wang YH, Sung RJ

The Application of Clinical Genetics 2013, 6:1-13

Published Date: 18 January 2013

Autologous bone marrow cell therapy for peripheral arterial disease

Botti C, Maione C, Coppola A, Sica V, Cobellis G

Stem Cells and Cloning: Advances and Applications 2012, 5:5-14

Published Date: 6 September 2012

High sensitivity C-reactive protein: a biomarker for heart failure in children with univentricular heart disease

Lowenthal A, Natal-Hernandez L, Lowenthal S, Hills NK, Bernstein HS

Current Biomarker Findings 2012, 2:57-62

Published Date: 29 August 2012

Regenerative treatment using a radioelectric asymmetric conveyor as a novel tool in antiaging medicine: an in vitro beta-galactosidase study

Rinaldi S, Maioli M, Santaniello S, Castagna A, Pigliaru GF, Gualini S, Margotti ML, Carta A, Fontani V, Ventura C

Clinical Interventions in Aging 2012, 7:191-194

Published Date: 29 June 2012